Figure 5.

Experimental confirmation of the in vitro kinase activity of compounds and their scaffolds screened from a chemical library. Dose–response curves of the top-ranked compounds from the Bionet chemical library for EGFR tyrosine kinase inhibitor activity (A) and CDK2 inhibitor activity (B). Inactive compounds (cutoff of 100 μM in IC₅₀ value) are not shown. Color of lines in A and B is the same as in Figure 4. Compounds 18, 36, 21, 35, and 37 are corresponding to the curves in A from left to right. Compounds 26 ([4-amino-2-(tert-butylamino)-1,3-thiazol-5-yl](4-chlorophenyl)methanone) and 23 are corresponding to the curves in B from left to right. (C) Max-MCSs and publication status are similar to Figure 4 for the EGFR and CDK2. See Table I for compound names of the numbered compounds.